Molecular Insights into Therapeutic Potentials of Hybrid Compounds Targeting Alzheimer’s Disease

[1]  Wenjian Tang,et al.  Novel cannabidiol-carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease. , 2021, European journal of medicinal chemistry.

[2]  S. Dastmalchi,et al.  Hybridization‐based design of novel anticholinesterase indanone–carbamates for Alzheimer's disease: Synthesis, biological evaluation, and docking studies , 2021, Archiv der Pharmazie.

[3]  I. Doytchinova,et al.  A Novel Galantamine-Curcumin Hybrid as a Potential Multi-Target Agent against Neurodegenerative Disorders , 2021, Molecules.

[4]  K. Langa,et al.  Financial Presentation of Alzheimer Disease and Related Dementias. , 2020, JAMA internal medicine.

[5]  O. Firuzi,et al.  Novel N‐benzylpiperidine derivatives of 5‐arylisoxazole‐3‐carboxamides as anti‐Alzheimer's agents , 2020, Archiv der Pharmazie.

[6]  Kevin L Nguyen,et al.  Evaluation of rivastigmine in Alzheimer's disease. , 2020, Neurodegenerative disease management.

[7]  I. Doytchinova,et al.  Galantamine-Curcumin Hybrids as Dual-Site Binding Acetylcholinesterase Inhibitors , 2020, Molecules.

[8]  R. Khoury,et al.  Deciphering Alzheimer’s disease: predicting new therapeutic strategies via improved understanding of biology and pathogenesis , 2020, Expert opinion on therapeutic targets.

[9]  T. Govindaraju,et al.  Antioxidant Berberine-Derivative Inhibits Multifaceted Amyloid Toxicity , 2020, iScience.

[10]  G. Batiha,et al.  Physostigmine: A Plant Alkaloid Isolated from Physostigma venenosum: A Review on Pharmacokinetics, Pharmacological and Toxicological Activities , 2020 .

[11]  O. Forlenza,et al.  Early diagnosis and treatment of Alzheimer’s disease: new definitions and challenges , 2020, Revista brasileira de psiquiatria.

[12]  K. Chand,et al.  Novel tacrine–benzofuran hybrids as potential multi-target drug candidates for the treatment of Alzheimer’s Disease , 2019, Journal of enzyme inhibition and medicinal chemistry.

[13]  Wenmin Liu,et al.  Apigenin-rivastigmine hybrids as multi-target-directed liagnds for the treatment of Alzheimer's disease. , 2019, European journal of medicinal chemistry.

[14]  S. Kang,et al.  Polyphenolic Biflavonoids Inhibit Amyloid-Beta Fibrillation and Disaggregate Preformed Amyloid-Beta Fibrils , 2019, Biomolecules & therapeutics.

[15]  B. Larijani,et al.  Design, Synthesis, Molecular Docking, and Cholinesterase Inhibitory Potential of Phthalimide‐Dithiocarbamate Hybrids as New Agents for Treatment of Alzheimer's Disease , 2019, Chemistry & biodiversity.

[16]  Zall Hirschstein,et al.  MA-[d-Leu-4]-OB3, a Small Molecule Synthetic Peptide Leptin Mimetic, Mirrors the Cognitive Enhancing Action of Leptin in a Mouse Model of Type 1 Diabetes Mellitus and Alzheimer’s Disease-Like Cognitive Impairment , 2019, International Journal of Peptide Research and Therapeutics.

[17]  D. G. Parambi,et al.  Advancements in nanotherapeutics for Alzheimer’s disease: current perspectives , 2019, The Journal of pharmacy and pharmacology.

[18]  Weizhong Tang,et al.  Novel chromanone-dithiocarbamate hybrids as multifunctional AChE inhibitors with β-amyloid anti-aggregation properties for the treatment of Alzheimer's disease. , 2019, Bioorganic chemistry.

[19]  K. Sharma.  Cholinesterase inhibitors as Alzheimer's therapeutics , 2019, Molecular medicine reports.

[20]  E. Laurini,et al.  New flavonoid – N,N-dibenzyl(N-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties , 2019, Journal of enzyme inhibition and medicinal chemistry.

[21]  Jianrong Xu,et al.  Bis(9)-(−)-Meptazinol, a novel dual-binding AChE inhibitor, rescues cognitive deficits and pathological changes in APP/PS1 transgenic mice , 2018, Translational Neurodegeneration.

[22]  Jing Liu,et al.  Design, synthesis and biological evaluation of new coumarin-dithiocarbamate hybrids as multifunctional agents for the treatment of Alzheimer's disease. , 2018, European journal of medicinal chemistry.

[23]  H. Cai,et al.  AGE-induced neuronal cell death is enhanced in G2019S LRRK2 mutation with increased RAGE expression , 2018, Translational Neurodegeneration.

[24]  E. Candeias,et al.  Donepezil structure-based hybrids as potential multifunctional anti-Alzheimer’s drug candidates , 2018, Journal of enzyme inhibition and medicinal chemistry.

[25]  I. Doytchinova,et al.  Docking‐based design and synthesis of galantamine–camphane hybrids as inhibitors of acetylcholinesterase , 2017, Chemical biology & drug design.

[26]  F. J. Luque,et al.  Design, synthesis and multitarget biological profiling of second-generation anti-Alzheimer rhein-huprine hybrids. , 2017, Future medicinal chemistry.

[27]  C. Pérez,et al.  Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia. , 2017, European journal of medicinal chemistry.

[28]  R. León,et al.  Novel Multitarget Hybrid Compounds for the Treatment of Alzheimer's Disease. , 2017, Current topics in medicinal chemistry.

[29]  Yan Li,et al.  Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease. , 2017, Bioorganic & medicinal chemistry.

[30]  G. Nesi,et al.  Discovery of novel rivastigmine-hydroxycinnamic acid hybrids as multi-targeted agents for Alzheimer's disease. , 2017, European journal of medicinal chemistry.

[31]  Weiliang Zhu,et al.  Advances in the study of berberine and its derivatives: a focus on anti-inflammatory and anti-tumor effects in the digestive system , 2016, Acta Pharmacologica Sinica.

[32]  Z. Cai,et al.  Role of berberine in Alzheimer’s disease , 2016, Neuropsychiatric disease and treatment.

[33]  M. Nehls.  Unified theory of Alzheimer’s disease (UTAD): implications for prevention and curative therapy , 2016, Journal of molecular psychiatry.

[34]  Changzhong Chen,et al.  Design, synthesis and evaluation of novel ferulic acid-memoquin hybrids as potential multifunctional agents for the treatment of Alzheimer's disease. , 2016, Bioorganic & medicinal chemistry letters.

[35]  M. Abdollahi,et al.  Berberine and neurodegeneration: A review of literature , 2015, Pharmacological reports : PR.

[36]  Xingshu Li,et al.  Tacrine–propargylamine derivatives with improved acetylcholinesterase inhibitory activity and lower hepatotoxicity as a potential lead compound for the treatment of Alzheimer’s disease , 2015, Journal of enzyme inhibition and medicinal chemistry.

[37]  Yan Li,et al.  Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer's disease. , 2015, Bioorganic & medicinal chemistry.

[38]  Arun K. Ghosh,et al.  Organic Carbamates in Drug Design and Medicinal Chemistry , 2015, Journal of medicinal chemistry.

[39]  M. Ferrari,et al.  Advances in Nanotechnology-Based Drug Delivery Platforms and Novel Drug Delivery Systems , 2015 .

[40]  Reisa A. Sperling,et al.  Alzheimer's disease , 2015, Nature Reviews Disease Primers.

[41]  Li Tang,et al.  Design, synthesis and evaluation of rivastigmine and curcumin hybrids as site-activated multitarget-directed ligands for Alzheimer's disease therapy. , 2014, Bioorganic & medicinal chemistry.

[42]  J. Arias.  Nanotechnology and Drug Delivery, Volume One : Nanoplatforms in Drug Delivery , 2014 .

[43]  F. J. Luque,et al.  Synthesis and multitarget biological profiling of a novel family of rhein derivatives as disease-modifying anti-Alzheimer agents. , 2014, Journal of medicinal chemistry.

[44]  Claudio Viegas,et al.  Donepezil: an important prototype to the design of new drug candidates for Alzheimer's disease. , 2014, Mini reviews in medicinal chemistry.

[45]  Manjinder Singh,et al.  Acetylcholinesterase inhibitors as Alzheimer therapy: from nerve toxins to neuroprotection. , 2013, European journal of medicinal chemistry.

[46]  Yang Sun,et al.  Synthesis and evaluation of multi-target-directed ligands against Alzheimer's disease based on the fusion of donepezil and ebselen. , 2013, Journal of medicinal chemistry.

[47]  José Marco-Contelles,et al.  Recent advances in the multitarget‐directed ligands approach for the treatment of Alzheimer's disease , 2013, Medicinal research reviews.

[48]  W. Jia,et al.  Effects and mechanisms of berberine in diabetes treatment , 2012 .

[49]  M. Decker,et al.  Tacrine-silibinin codrug shows neuro- and hepatoprotective effects in vitro and pro-cognitive and hepatoprotective effects in vivo. , 2012, Journal of medicinal chemistry.

[50]  M. Sabbagh,et al.  Novel Therapeutics in Alzheimer's Disease , 2012, International journal of Alzheimer's disease.

[51]  Hank F Kung,et al.  The β-Amyloid Hypothesis in Alzheimer's Disease: Seeing Is Believing. , 2012, ACS medicinal chemistry letters.

[52]  Hong Liang,et al.  Hybrids of Oxoisoaporphine‐Tacrine Congeners: Novel Acetylcholinesterase and Acetylcholinesterase‐Induced β‐Amyloid Aggregation Inhibitors. , 2012 .

[53]  M. Sabbagh,et al.  New Acetylcholinesterase Inhibitors for Alzheimer's Disease , 2011, International journal of Alzheimer's disease.

[54]  Xingshu Li,et al.  Benzenediol-berberine hybrids: multifunctional agents for Alzheimer's disease. , 2011, Bioorganic & medicinal chemistry.

[55]  Hong Liang,et al.  Hybrids of oxoisoaporphine-tacrine congeners: novel acetylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation inhibitors. , 2011, European journal of medicinal chemistry.

[56]  B. Hyman,et al.  Neuropathological alterations in Alzheimer disease. , 2011, Cold Spring Harbor perspectives in medicine.

[57]  J. Morris,et al.  Alzheimer’s Disease: The Challenge of the Second Century , 2011, Science Translational Medicine.

[58]  M. Irizarry.  Biomarkers of Alzheimer disease in plasma , 2004, NeuroRX.

[59]  S. Mandel,et al.  Multifunctional neuroprotective derivatives of rasagiline as anti-alzheimer’s disease drugs , 2011, Neurotherapeutics.

[60]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[61]  N. Greig,et al.  Phenserine efficacy in Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[62]  N. Greig,et al.  Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. , 2010, Bioorganic & medicinal chemistry.

[63]  V. Tumiatti,et al.  Tacrine derivatives and Alzheimer's disease. , 2010, Current medicinal chemistry.

[64]  Xingshu Li,et al.  Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors. , 2010, Bioorganic & medicinal chemistry.

[65]  L. Gediya,et al.  Promise and challenges in drug discovery and development of hybrid anticancer drugs , 2009, Expert opinion on drug discovery.

[66]  C. Pérez,et al.  Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease. , 2009, Journal of medicinal chemistry.

[67]  V. Haroutunian,et al.  Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons , 2009, Neurology.

[68]  D. Small.  Dysregulation of Calcium Homeostasis in Alzheimer’s Disease , 2009, Neurochemical Research.

[69]  F. Ahmad,et al.  CNS drug delivery systems: novel approaches. , 2009, Recent patents on drug delivery & formulation.

[70]  Luigi Ferrucci,et al.  Association of adiposity status and changes in early to mid-adulthood with incidence of Alzheimer's disease. , 2008, American journal of epidemiology.

[71]  Zhaohui Zhao,et al.  Chemistry, natural sources, dietary intake and pharmacokinetic properties of ferulic acid: A review. , 2008, Food chemistry.

[72]  F. J. Luque,et al.  Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation. , 2008, Journal of medicinal chemistry.

[73]  B. Meunier,et al.  Hybrid molecules with a dual mode of action: dream or reality? , 2008, Accounts of chemical research.

[74]  Maurizio Recanatini,et al.  Multi-target-directed ligands to combat neurodegenerative diseases. , 2008, Journal of medicinal chemistry.

[75]  Shrikant D. Mishra,et al.  The effect of curcumin (turmeric) on Alzheimer's disease: An overview , 2008, Annals of Indian Academy of Neurology.

[76]  R. Swerdlow,et al.  Pathogenesis of Alzheimer’s disease , 2007, Clinical interventions in aging.

[77]  N. Greig,et al.  Editorial [Hot Topic: Advances in Alzheimer Therapy: Development of Innovative New Strategies (Guest Editors: Nigel H. Greig, Ezio Giacobini and Debomoy K. Lahiri)] , 2007 .

[78]  J. Klein.  Phenserine , 2007, Expert opinion on investigational drugs.

[79]  E. Barreiro,et al.  Molecular hybridization: a useful tool in the design of new drug prototypes. , 2007, Current medicinal chemistry.

[80]  R. Deane,et al.  Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. , 2007, Current Alzheimer research.

[81]  N. Greig,et al.  Advances in Alzheimer therapy: development of innovative new strategies. , 2007, Current Alzheimer research.

[82]  Keith F. Tipton,et al.  The therapeutic potential of monoamine oxidase inhibitors , 2006, Nature Reviews Neuroscience.

[83]  C. Pérez,et al.  Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties. , 2006, Journal of medicinal chemistry.

[84]  R. Mrak,et al.  Potential inflammatory biomarkers in Alzheimer's disease. , 2006, Journal of Alzheimer's disease : JAD.

[85]  N. Greig,et al.  Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent , 2005 .

[86]  G. Bottini,et al.  Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease , 2005, Current medical research and opinion.

[87]  Tomás Pérez-Acle,et al.  Acetylcholinesterase-amyloid-beta-peptide interaction: effect of Congo Red and the role of the Wnt pathway. , 2005, Current Alzheimer research.

[88]  N. Greig,et al.  Novel Anticholinesterases Based on the Molecular Skeletons of Furobenzofuran and Methanobenzodioxepine , 2005 .

[89]  M. Recanatini,et al.  Acetylcholinesterase inhibitors as a starting point towards improved Alzheimer's disease therapeutics. , 2004, Current pharmaceutical design.

[90]  D. Butterfield.  Amyloid beta-peptide [1-42]-associated free radical-induced oxidative stress and neurodegeneration in Alzheimer's disease brain: mechanisms and consequences. , 2003, Current medicinal chemistry.

[91]  E. Giacobini,et al.  Cholinergic function and Alzheimer's disease , 2003, International journal of geriatric psychiatry.

[92]  Pritam Das,et al.  NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo , 2003 .

[93]  C. Geula,et al.  Neurobiology of butyrylcholinesterase , 2003, Nature Reviews Neuroscience.

[94]  J. Fenstermacher,et al.  Overview of the Structure and Function of the Blood-Brain Barrier in vivo , 2001 .

[95]  K. Goa,et al.  Galantamine: a review of its use in Alzheimer's disease. , 2000, Drugs.

[96]  N. Greig,et al.  Kinetics of human acetylcholinesterase inhibition by the novel experimental Alzheimer therapeutic agent, tolserine. , 2000, Biochemical pharmacology.

[97]  M. Weinstock,et al.  Selectivity of Cholinesterase Inhibition , 1999 .

[98]  A. Hurley,et al.  Past, present, and future directions for Alzheimer research. , 1999, Alzheimer disease and associated disorders.

[99]  M. Sarter,et al.  Cognitive functions of cortical acetylcholine: toward a unifying hypothesis , 1997, Brain Research Reviews.

[100]  J. Coyle,et al.  Oxidative stress in neurodegenerative diseases. , 1996, Annual review of pharmacology and toxicology.

[101]  R. Stelzmann,et al.  An english translation of alzheimer's 1907 paper, “über eine eigenartige erkankung der hirnrinde” , 1995, Clinical anatomy.

[102]  M. Hasselmo,et al.  Cholinergic modulation of cortical associative memory function. , 1992, Journal of neurophysiology.

[103]  Stephen B. Dunnett,et al.  The basal forebrain-cortical cholinergic system: interpreting the functional consequences of excitotoxic lesions , 1991, Trends in Neurosciences.

[104]  W. V. van Gool,et al.  [Tacrine in the treatment of Alzheimer's disease]. , 1991, Nederlands tijdschrift voor geneeskunde.

[105]  B. Katz,et al.  Ionic Requirements of Synaptic Transmitter Release , 1967, Nature.